EXEL

EXELIXIS, INC.

Tremor tracks 12 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

3 insiders sold shares within a monthSince May 26, 2026+1.5

Trials

EXELExelixis
2Calm
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Signing up patientsPhase 2/3440 patientsMain results: Jun 30, 2029
EXELExelixis
2Calm
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Invite-only sign-upPhase 35,000 patientsMain results: May 31, 2030
EXELExelixis
2Calm
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Signing up patientsPhase 2100 patientsMain results: Feb 29, 2028
EXELExelixis
2Calm
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Running, no new patientsPhase 3855 patientsMain results: Jan 31, 2022
EXELExelixis
2Calm
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Running, no new patientsPhase 3187 patientsMain results: Aug 19, 2020
EXELExelixis
2Calm
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Not started yetPhase 260 patientsMain results: Jun 15, 2028
EXELExelixis
2Calm
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Signing up patientsPhase 3600 patientsMain results: Apr 5, 2030
EXELExelixis
2Calm
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Running, no new patientsPhase 3317 patientsMain results: Dec 15, 2026
EXELExelixis
2Calm
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Running, no new patientsPhase 3901 patientsMain results: Jun 16, 2026
EXELExelixis
2Calm
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Running, no new patientsPhase 3575 patientsMain results: Apr 19, 2024
EXELExelixis
2Calm
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Running, no new patientsPhase 3837 patientsMain results: Nov 30, 2021
EXELExelixis
2Calm
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Running, no new patientsPhase 2/3600 patientsMain results: Aug 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

7 sales (3 not pre-planned) · 0 purchases

Beckerle Mary CBoard member · Aug 10, 2026Sold 9,812 sharesabout $527 thousand · pre-planned
WYSZOMIERSKI JACK LBoard member · Jun 1, 2026Sold 3,925 sharesabout $198 thousand · pre-planned
Eckhardt Sue GailBoard member · Jun 1, 2026Sold 9,812 sharesabout $492 thousand · pre-planned
Aftab DanaEVP, Research and Development · May 26, 2026Sold 43,451 sharesabout $2.2 million · not pre-planned
Haley Patrick J.EVP, Commercial · May 20, 2026Sold 32,110 sharesabout $1.6 million · not pre-planned
Senner Christopher J.EVP and CFO · May 18, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.